Clearance Summary
ABRO 1, RESITON GINGIVA, PRIME and THERAPON TRANSPA received FDA 510(k) clearance under submission number K200676, sponsored by Zirkonzahn Srl. The device was reviewed via the Traditional premarket notification pathway and assigned to the Dental review panel. The statutory decision date of record is 2020-07-08.
- Submission: K200676
- Applicant / Sponsor: Zirkonzahn Srl
- Clearance pathway: Traditional
- Review panel: Dental
- Device class: Class II
- Regulation citation: 21 CFR 872.3770
- Decision date: 2020-07-08
Classification & Regulation
This clearance is catalogued under FDA product code EBG and 21 CFR 872.3770, within the Dental review panel as a Class II device.